A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Top Cited Papers
- 12 February 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Endocrinology
- Vol. 12 (4), 192-202
- https://doi.org/10.1038/nrendo.2016.11
Abstract
No abstract availableKeywords
This publication has 157 references indexed in Scilit:
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- Alternative splicing results in RET isoforms with distinct trafficking propertiesMolecular Biology of the Cell, 2012
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialThe Lancet Oncology, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysisThe American Journal of Surgery, 2010
- Mechanisms of chromosomal rearrangements in solid tumors: The model of papillary thyroid carcinomaMolecular and Cellular Endocrinology, 2010
- DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cellsOncogene, 2010
- Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomasBritish Journal of Cancer, 2009
- Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005Cancer Epidemiology, Biomarkers & Prevention, 2009
- Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's ThyroiditisThe Laryngoscope, 1997